In recent decades, rapid progression of monoclonal antibody (mAb) development has culminated in approvals for more than one hundred therapeutics in the United States. mAbs enhance the immune response ...
Research and development of monoclonal antibody (mAb) therapeutics is a vast and expanding area of drug discovery, largely due to mAb potential for high specificity and affinity towards target ...
In therapeutic antibody development the fragment crystallizable (Fc) region is far more than just an antigen-binding aid; it's role is much larger, functioning as the antibody’s functional control ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2006 ASCO Annual Meeting. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback